Abbott Laboratories is set to pull back the curtain on its first-quarter 2026 performance next week, and Wall Street will be watching closely — especially after the healthcare giant closed out 2025 with a streak of momentum it’s eager to extend.
The company will release its first-quarter 2026 financial results on Thursday, April 16, before the market opens, followed by a live webcast at 8 a.m. Central time (9 a.m. Eastern), accessible through Abbott’s investor relations portal. The report lands at a pivotal moment — one where the company’s own guidance has set a high bar, and investors will want to see whether the numbers hold up against that promise.
A Company That’s Been Here Before
Abbott isn’t new to this kind of scrutiny. The company has been hosting quarterly earnings calls for years, including previous first-quarter calls dating back to early 2024, and an established cadence that keeps institutional investors on a tight schedule. The Q4 2025 earnings call, for instance, was held on January 22, 2026, at 8 a.m. CST — complete with a press release and supporting materials that laid out a company firing on most cylinders.
That Q4 report was, by most measures, a strong one. Sales rose 3.8% excluding COVID testing revenue — a figure that strips out the volatile pandemic-era diagnostics business and shows what the underlying company is actually doing. Adjusted earnings per share came in at $1.50, representing 12% growth. Adjusted operating margin climbed to 25.8%, up 150 basis points year-over-year. Not bad for a company that operates across four sprawling business segments on six continents.
The Guidance That Turned Heads
What really got attention, though, was what Abbott said about the year ahead. During the Q4 call, management didn’t just report results — they made a statement. “We expect 2026 to be another year powered by innovation, operational excellence, and strategic execution,” executives said. “As we announced this morning, we forecast the midpoint of our 2026 organic sales growth range to be 7% and the midpoint of our adjusted earnings per share range to reflect 10% growth.”
That 10% EPS growth target — with full-year adjusted EPS guidance of $5.55 to $5.80 — is the kind of forward commitment that either ages very well or becomes a millstone. The Q1 report will serve as the first real data point on whether Abbott can deliver. And given that the company’s investor page already references double-digit earnings growth from 2025, there’s a pattern here management clearly wants to sustain.
What Abbott Actually Is
For those less familiar with the company’s scope — it’s considerable. Abbott is a global healthcare conglomerate with roughly 122,000 employees and operations spanning diagnostics, medical devices, nutritional products, and branded generic medicines, all reaching more than 160 countries. It’s the kind of diversified portfolio that can cushion a bad quarter in one segment with a strong one in another — though it also means there’s always something to interrogate when the numbers land.
The company’s breadth is both its armor and its complexity. Diagnostics, for example, have been a wildcard ever since COVID testing revenue began its long fade. Medical devices — particularly cardiovascular and diabetes care — have been a consistent bright spot. Nutritionals face their own competitive pressures. Investors tend to care most about which segment is carrying the others in any given quarter.
What to Watch on April 16
So what exactly should observers be listening for? Organic sales growth will be the headline number, with the 7% midpoint guidance serving as the benchmark. Any deviation — up or down — will set the tone for the rest of the call. Margin performance matters too; a 150-basis-point improvement in Q4 was impressive, and analysts will want to know whether that’s a trend or a one-quarter phenomenon.
Still, it’s worth remembering the broader context. Abbott has navigated earnings cycles through everything from supply chain disruptions to regulatory headwinds — including the fallout from its infant formula recall years back — and has generally come through with its long-term trajectory intact. That institutional resilience doesn’t guarantee a clean quarter, but it does mean the company tends to have answers ready when the hard questions come.
The webcast goes live at 8 a.m. Central on April 16. Whether it’s a victory lap or a course-correction moment, the healthcare world will be tuned in.
Ten percent earnings growth is a bold promise to make at the start of a year. Now comes the part where Abbott has to actually keep it.
